Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...

Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

Lineage Cell Therapeutics Inc (LCTX) extends its cash runway and progresses in key partnerships, despite facing regulatory ...

Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

Brian Alexander, M.D., M.P.H., most recently was an SVP for R&D at Roche/Genentech, where he worked to leverage data ... Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing ...

Sangamo Therapeutics Inc (NASDAQ:SGMO) has transformed from a Phase 1/2 company ... The company has signed a neurology ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

Conjunctival breach and a late onset are common in cases of endophthalmitis associated with implantation of an anti-VEGF delivery device.

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th American Society of Hematology, or ASH, annual meeting and ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...